8-K


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	April 14, 2025
Date of Report (date of earliest event reported)

IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)

Delaware		000-27598	77-0210467
(State or other jurisdiction of incorporation or organization)		(Commission File Number)	(I.R.S. Employer Identification Number)
1212 Terra Bella Avenue Mountain View, California 94043
(Address of principal executive offices, including zip code)

(650) 940-4700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

     Title of Class

     Trading
Symbol

     Name of Exchange on Which Registered

     Common Stock, par value $0.01 per share

     IRIX

     Nasdaq Capital Market

Item 2.02. Results of Operations and Financial Condition.

On April 14, 2025, IRIDEX Corporation (the "Company") announced its preliminary, unaudited operational and financial results for its first fiscal quarter ended March 29, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.


(d)	Exhibits


Exhibit No.		Description

99.1		Press Release dated April 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		IRIDEX CORPORATION

	By:	/s/ Patrick Mercer
		Patrick Mercer
		Chief Executive Officer

Date: April 14, 2025

-3-

Exhibit 99.1

Iridex Announces Preliminary Operational and Financial Results for the First Quarter 2025

MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) – Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the first quarter ended March 29, 2025.

First Quarter 2025 Results

•

Total revenue is expected to be between $11.8 million and $12.0 million, compared to $11.8 million in the comparable quarter of 2024

•

Sold approximately 13,900 Cyclo G6 probes, compared to 13,300 in the prior year quarter

•

Sold approximately 24 Cyclo G6 Laser Systems, compared to 22 in the prior year quarter

•

Cash and cash equivalents as of March 29, 2025 were $7.2 million

President and CEO Patrick Mercer commented, "As announced last month, we are pre-announcing our first quarter results in order to highlight (i) the stabilization of our business and (ii) the Company’s improved financial condition following the strategic investment by Novel Inspiration International Co., Ltd. (“Novel”). We have delivered top line revenue increases versus the prior year in each of the last two quarters, even while significantly reducing operating expenses. We are exposed to external factors like changes in tariff policies, but we remain capable of achieving breakeven or better performance at historical revenue levels. On April 16, 2025, we will hold an investor call to introduce Iridex and Novel’s strategic vision for the Company."

These preliminary results are based on management’s initial analysis of operations for the quarter ended March 29, 2025, and are subject to further internal review, potential adjustments and review by the Company’s external auditors.

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and

internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning financial and operating results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2025. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

Media Contact

Joan Staufer

[email protected]

Investor Relations Contact

Philip Taylor

Gilmartin Group

[email protected]